Cellectar Biosciences To Present Three Posters For Its Radiopharmaceutical Candidate At American Society Of Hematology Annual Meeting

Benzinga · 17h ago

Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of cancer therapies, today announced that three posters highlighting compelling data and clinical progress for its lead radiopharmaceutical candidate, iopofosine I 131 in Waldenström macroglobulinemia (WM), will be presented at the upcoming American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 12 – 15 in New Orleans, Louisiana.